The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation

Laurent Azoulay; Sophie Dell’Aniello; Teresa Simon; Christel Renoux; Samy Suissa

doi:10.1160/TH12-08-0542

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2013; 109(03): 431-439
DOI: 10.1160/TH12-08-0542

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation

Authors

Laurent Azoulay

¹Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada

²Department of Oncology, McGill University, Montreal, Quebec, Canada
Sophie Dell’Aniello

¹Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
Teresa Simon

³Bristol–Myers Squibb, Lawrenceville, New Jersey, USA
Christel Renoux

¹Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada

⁴Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada
Samy Suissa

¹Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada

⁵Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada

Abstract

Summary

Patients with atrial fibrillation (AF) often receive, in addition to warfarin, antithrombotic drugs to manage other comorbid conditions. To date, few population-based studies have quantified the bleeding risk associated with the concurrent use of these therapies. The United Kingdom General Practice Research Database was used to identify a cohort of 70,760 patients newly-diagnosed with AF between 1993 and 2008. A nested case-control analysis was conducted within that cohort, and conditional logistic regression was used to estimate adjusted rate ratios (RRs) of bleeding associated with current use of warfarin, aspirin, and clopidogrel in single therapy, as well as in dual and triple therapy, as compared with non-use of any therapy. A total of 10,850 patients experienced a bleeding event during follow-up. In single therapy, warfarin was associated with the highest increased risk (RR: 2.08, 95% confidence interval [CI]: 1.95–2.23), followed by clopidogrel (RR: 1.57, 95% CI: 1.37–1.81) and aspirin (RR: 1.25, 95% CI: 1.17–1.34). In dual therapy, combinations containing warfarin were associated with a higher increased risk (warfarin-aspirin: RR: 2.87, 95% CI: 2.58–3.19, and warfarin-clopidogrel: RR: 2.74, 95% CI: 2.14–3.51), than those not containing warfarin (aspirin-clopidogrel: RR: 1.68, 95% CI: 1.44–1.97). Triple therapy of warfarin-aspirin-clopidogrel was associated with the highest increased risk (RR: 3.75, 95% CI: 2.71–5.19). This large population-based study suggests that while all antithrombotic therapies are associated with an elevated risk of bleeding, the risks increase in an additive fashion with dual and triple therapy, particularly in combinations containing warfarin.

Keywords

Atrial fibrillation - antithrombotic therapies - bleeding - populationbased

Full Text

References

References
1 Camm AJ. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
2 Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
3 Albers GW. et al. Stroke prevention in nonvalvular atrial fibrillation: a review of prospective randomized trials. Ann Neurol 1991; 30: 511-518.
4 Majeed A. et al. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research database. Heart 2001; 86: 284-288.
5 Fang MC. et al. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med 2004; 164: 55-60.
6 Dewilde S. et al. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart 2006; 92: 1064-1070.
7 Silber S. et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804-847.
8 Perez-Gomez F. et al. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 2004; 44: 1557-1566.
9 Flaker GC. et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J 2006; 152: 967-973.
10 Dentali F. et al. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med 2007; 167: 117-124.
11 Hansen ML. et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170: 1433-1441.
12 Shireman TI. et al. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke 2004; 35: 2362-2367.
13 Johnson SG. et al. Outcomes associated with combined antiplatelet and anticoagulant therapy. Chest 2008; 133: 948-954.
14 Lamberts M. et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 2012; 126: 1185-1193.
15 Garcia DA. et al. New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb Haemost 2010; 104: 1099-1105.
16 Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997; 350: 1097-1099.
17 Garcia Rodriguez LA, Perez GS. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998; 45: 419-425.
18 Jick H. et al. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991; 302: 766-768.
19 Lawrenson R. et al. Clinical information for research; the use of general practice databases. J Public Health Med 1999; 21: 299-304.
20 Lawrenson R. et al. Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol 2000; 49: 591-596.
21 Jick SS. et al. Validity of the general practice research database. Pharmacotherapy 2003; 23: 686-689.
22 Suissa S. Novel approaches to pharmacoepidemiology study design and statistical analysis. In: Pharmacoepidemiology. 4th ed. Chichester, England: John Wiley Sons;; 2005. pp. 811-829
23 Essebag V. et al. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 2005; 5: 5.
24 Essebag V. et al. The nested case-control study in cardiology. Am Heart J 2003; 146: 581-590.
25 Go AS. et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?. J Am Med Assoc 2003; 290: 2685-2692.
26 Rosendaal FR. et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239.
27 Azoulay L. et al. A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study. BMC Cardiovasc Disord 2012; 12: 49.
28 Gage BF. et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. J Am Med Assoc 2001; 285: 2864-2870.
29 Lip GY. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272.
30 Pisters R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100.
31 Freedman MD. Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol 1992; 32: 196-209.
32 Born G, Patrono C. Antiplatelet drugs. Br J Pharmacol 2006; 147 (Suppl. 01) S241-S251.
33 Hart RG. et al. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995; 26: 1471-1477.
34 Lip GY. et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011; 106: 997-1011.
35 Olesen JB. et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011; 106: 739-749.
36 Anand S. et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007; 357: 217-227.
37 Faxon DP. et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011; 106: 572-584.
38 Lip GY. et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010; 103: 13-28.
39 Lip GY. et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2010; 31: 1311-1318.
40 Huber K. et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost 2011; 106: 569-571.
41 Dewilde W. et al. The WOEST Trial: First randomised trial comparing two regimens with and without aspirin in patients on oral anticoagulant therapy undergoing coronary stenting. Available at: http://spo.escardio.org/SessionDetails.aspx?eevtid=54&fp=3931&doc=slides Accessed September 20, 2012.
42 Connolly SJ. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
43 Patel MR. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
44 Granger CB. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
45 Weitz JI. et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010; 104: 633-641.
46 Eikelboom JW. et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363-2372.